From GlobeNewswire: 2025-04-14 17:50:00

Applied Therapeutics, Inc. made key senior appointments, including John H. Johnson as Executive Chairman and Todd F. Baumgartner as Chief Regulatory Officer. The company continues to evaluate responses to FDA’s Complete Response Letter for govorestat in Classic Galactosemia. Financially, the company reported a net loss of $105.6 million for the year ended December 31, 2024, with cash and cash equivalents of $79.4 million.



Read more at GlobeNewswire:: Applied Therapeutics Reports Fourth Quarter and Year-end